InvestSMART

AVITA Medical, Inc. (ASX:AVH)

ALERT: Price-sensitive ASX Announcement for AVH
Current share price for AVH : $1.365 0.275 (25.23%)+
Announcement
Release
13 Feb 2026 9:41AM
Price at Release
$1.090
Full Release
download
Summary
AVITA Medical, Inc., a leading company in therapeutic acute wound care, reported its fourth quarter and full year 2025 financial results, announcing a total revenue of $17.6 million for Q4 and $71.6 million for the entire year, representing an 11% increase from 2024. Despite facing reimbursement challenges throughout 2025, the company achieved a gross profit margin of 81.2% for Q4 and 82.1% for the full year. Net loss for the year was $48.6 million, improved from $61.8 million in the prior year. AVITA's interim CEO Cary Vance highlighted the company's strategic shift towards better execution and commercialization, while its CFO David O’Toole emphasized improvements in cash efficiency and cost structure. The company also refinanced its debt with Perceptive Advisors to strengthen its capital structure. Looking forward, AVITA expects a 12% to 19% revenue growth in 2026, with guidance set between $80 and $85 million.
Key Points
  • Total revenue for Q4 2025 was $17.6 million, a decrease from Q4 2024.
  • Full year 2025 revenue was $71.6 million, an 11% increase from 2024.
  • Gross profit margin for Q4 was 81.2%, and for the full year was 82.1%.
  • Net loss for 2025 was $48.6 million, improved from $61.8 million in 2024.
  • The company refinanced its debt under a new facility with Perceptive Advisors.
  • Financial guidance for 2026 predicts a 12% to 19% revenue growth.
  • AVITA's product RECELL received broader Medicare reimbursement coverage.
  • The company focused on improving cash efficiency and reducing costs in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.